Eli Lilly unveils shared innovation laboratory in San Francisco
Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.
Eli Lilly has unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise.
"Lilly is making this investment to help speed the discovery of medicines," said Dan Skovronsky, president of Lilly Research Laboratories and chief scientific officer, Eli Lilly and Company. "This model will enable scientists to do what they do best, in an environment that fosters scientific breakthrough. We're excited to see how it will impact our ability to deliver new solutions for patients."
Companies who work in Lilly Gateway Labs will have the opportunity to collaborate with Lilly on projects of mutual interest, participate in shared learning forums with Lilly experts and partners, and have the potential for financial investment from Lilly, venture funds, or both.
"Lilly chose the Bay Area as the location for Lilly Gateway Labs for many reasons, including the ability to tap into the hotbed of biotech innovation already based here," said Julie Gilmore, site head and chief operations officer, Lilly Gateway Labs. "We're excited to further extend our California footprint because of the supportive scientific environment which enables all aspects of drug discovery."
With over 65,000 sq. ft of space, Lilly Gateway Labs offers 32 state-of-the-art, flexibly designed private lab modules. Each module includes lab space for six to eight scientists, office space, and work stations. The space was designed with open areas for collaboration, where scientific symposia and programming will be hosted by Lilly for companies at the site as well as the broader Bay Area scientific community.
"Healthcare is the fastest growing sector of California's economy and Lilly Gateway Labs brings exciting opportunities for partnerships and innovation in drug research and development in South San Francisco that will help lead to groundbreaking therapies and improved patient care," said Rob Lapsley, President and CEO, California Business Roundtable. "California's life sciences industry is one of the nation's – and the world's – leading life sciences hubs, and we look forward to their leadership in South San Francisco to grow new companies and jobs into the future."
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...